University of Limerick
Limerick, Ireland
NCT Number: NCT04266951
Chronic Obstructive Pulmonary Disease (COPD) is a pervasive, insidious condition associated with catastrophic socioeconomic, healthcare and personal implications. This proposal outlines how a group singing intervention, led by clinical personnel and a community singing leader, can address these challenges. Built upon existing ties between the Principal Investigator (PI) and local COPD support group, this project is co-designed by patients and clinicians. Modelled on similar interventions internationally, this project is pioneering in Ireland. Outputs will include a participant-led symposium and three community COPD choirs, in addition to a number of academic publications. This project is funded by the Irish Research Council (IRC) "New Foundations" scheme.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Limerick, Ireland
Brief Background:
Approximately 440,000 Irish people suffer from Chronic Obstructive Pulmonary Disease (COPD) (Health Service Executive (HSE), 2018) and it is the fourth most common cause of death, after lung cancer, heart disease and stroke. In addition to many physical issues, patients lack the physical endurance or confidence to participate fully in their lives, leading to isolation, social exclusion and co-morbid depression and anxiety. Addressing the management of people with COPD was highlighted as an urgent priority in the Government's 2017 National Healthcare Quality Reporting System annual report. This application proposes a community-based singing intervention replicating that successfully delivered by the British Lung Foundation (BLF) (https://www.blf.org.uk/support-for-you/singing-for-lung-health). This project is unique in Ireland, and builds on established ties between the (Principal Investigator) PI and the local COPD community. It is supported by COPD Support Ireland.
Study design:
Focus groups will be conducted with a sample from each group to support a qualitative evaluation of the intervention.
Participants:
Approximately 30 participants from each region will be invited to participate. Participants must have a diagnosis of COPD, must be clinically stable, and not have suffered an exacerbation in the 2 weeks prior to testing.
Participants have been sourced through the clinicians involved in this study, and the teaching contacts of the PI.
Procedures/Methods :
Planing stage: April/May 2019
Intervention stage: June/July 2019
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Group singing and breathing control training
Time frame: 8 weeks
Hospital Anxiety and Depression Scale (HADS). This questionnaire is widely used to measure anxiety and depression in a general medical population of patients. The questionnaire features seven questions for anxiety and seven for depression of which can be answered within 2 - 5 minutes. Each item is scored from 0-3 with a higher score indicating a greater presence of either anxiety or depression. Maximal (worst) score for either factor is 21.
Time frame: 8 weeks
Six minute walk test (6MWT). The 6MWT is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. This is measured in metres with levels of oxygen saturation and heart rate pre and post the test also recorded.
Time frame: 8 weeks
COPD Assessment test (CAT). The CAT is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. This is a patient-completed questionnaire assessing all aspects of the impact of COPD (cough, sputum, breathlessness, chest tightness, confidence, activity, sleep and energy levels) There are 8 questions on a 1 to 5 point scale. A higher score indicates more disease impact. Max score is 40.
Time frame: 8 weeks
Spirometry: The main measures recorded will include FEV1, or forced expiratory volume, is a measurement taken from a pulmonary function test. It calculates the amount of air that a person can force out of their lungs in 1 second.FVC, or Forced Vital Capacity, refers to the total amount of air that a person can exhale, will also be recorded. The ration of FEV1/FVC will also be recorded, as this provided an objective measure of the presence of disease. FEV1/FVC < 0.70). Disease severity in persons below a ratio of 0.7 is indicated by the value of FEV1. Mild FEV1 ≥ 80% predicted, Moderate 50% ≤ FEV1 < 80% predicted, Severe 30% ≤ FEV1 < 50% predicted, Very Severe FEV1 < 30% predicted.
Time frame: 8 weeks
Focus Groups: Focus group interviews with participants from each of the three choirs will be conducted to establish the effectiveness of the intervention, to establish what went well, and points for improvement in further iterations. Focus groups will be comprised of between 5 and 8 people, with a semi-structured design.
University of Limerick
Other
Acronym: Singstrong
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06149494
COPD, COPD Exacerbation Acute
London, United Kingdom
View Trial DetailsNCT05962645
COPD, Chronic Disease
Miami, Florida, United States
View Trial DetailsNCT05223114
Blood-Borne Infections, COPD
Kampala, Uganda
View Trial DetailsNCT05712226
Apnea, Asthma
Zurich, Canton of Zurich, Switzerland
View Trial Details